151 related articles for article (PubMed ID: 16845152)
1. Pergolide-associated valvular heart disease.
Waller EA; Kaplan J
Compr Ther; 2006; 32(2):94-101. PubMed ID: 16845152
[TBL] [Abstract][Full Text] [Related]
2. Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists.
Andersohn F; Garbe E
Mov Disord; 2009 Jan; 24(1):129-33. PubMed ID: 19170199
[TBL] [Abstract][Full Text] [Related]
3. Low incidence of restrictive valvulopathy in patients with Parkinson's disease on moderate dose of pergolide.
Růzicka E; Línková H; Penicka M; Ulmanová O; Nováková L; Roth J
J Neurol; 2007 Nov; 254(11):1575-8. PubMed ID: 17712588
[TBL] [Abstract][Full Text] [Related]
4. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.
Antonini A; Poewe W
Lancet Neurol; 2007 Sep; 6(9):826-9. PubMed ID: 17706566
[TBL] [Abstract][Full Text] [Related]
5. Pergolide and valvular heart disease: the lower the better?
Droogmans S; Cosyns B; Van Camp G
Eur J Echocardiogr; 2008 Nov; 9(6):717-8. PubMed ID: 18641388
[No Abstract] [Full Text] [Related]
6. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists.
Kvernmo T; Härtter S; Burger E
Clin Ther; 2006 Aug; 28(8):1065-1078. PubMed ID: 16982285
[TBL] [Abstract][Full Text] [Related]
7. Valvular heart disease and the use of dopamine agonists for Parkinson's disease.
Zanettini R; Antonini A; Gatto G; Gentile R; Tesei S; Pezzoli G
N Engl J Med; 2007 Jan; 356(1):39-46. PubMed ID: 17202454
[TBL] [Abstract][Full Text] [Related]
8. Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists.
Horvath J; Fross RD; Kleiner-Fisman G; Lerch R; Stalder H; Liaudat S; Raskoff WJ; Flachsbart KD; Rakowski H; Pache JC; Burkhard PR; Lang AE
Mov Disord; 2004 Jun; 19(6):656-62. PubMed ID: 15197703
[TBL] [Abstract][Full Text] [Related]
9. Cardiopulmonary complications of ergot-derivative dopamine agonists.
Rack MJ; Baran AS; Richert AC; Roffwarg HP
J Clin Psychiatry; 2004 Oct; 65(10):1429-30; author reply 1430. PubMed ID: 15491249
[No Abstract] [Full Text] [Related]
10. Pleuropulmonary disease due to pergolide use for restless legs syndrome.
Danoff SK; Grasso ME; Terry PB; Flynn JA
Chest; 2001 Jul; 120(1):313-6. PubMed ID: 11451859
[TBL] [Abstract][Full Text] [Related]
11. Additional insights into pergolide-associated valvular heart disease.
Lanier WL
Mayo Clin Proc; 2003 Jun; 78(6):684-6. PubMed ID: 12934776
[No Abstract] [Full Text] [Related]
12. Valvular heart disease in patients exposed to pergolide: insights from the clinical presentation.
Krishnaswami A; Albers KB; Fross RD; Jang JJ; Berkheimer SB; Kwai Ben VC; Vandeneeden SK
Pharmacoepidemiol Drug Saf; 2012 Mar; 21(3):276-80. PubMed ID: 22231899
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease.
Van Camp G; Flamez A; Cosyns B; Weytjens C; Muyldermans L; Van Zandijcke M; De Sutter J; Santens P; Decoodt P; Moerman C; Schoors D
Lancet; 2004 Apr; 363(9416):1179-83. PubMed ID: 15081648
[TBL] [Abstract][Full Text] [Related]
14. Pergolide associated cardiac valvulopathy based on Ontario administrative data.
Zadikoff C; Duong-Hua M; Sykora K; Marras C; Lang A; Rochon P
Can J Neurol Sci; 2008 May; 35(2):173-8. PubMed ID: 18574930
[TBL] [Abstract][Full Text] [Related]
15. Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study.
Junghanns S; Fuhrmann JT; Simonis G; Oelwein C; Koch R; Strasser RH; Reichmann H; Storch A
Mov Disord; 2007 Jan; 22(2):234-8. PubMed ID: 17094087
[TBL] [Abstract][Full Text] [Related]
16. Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists.
Kim JY; Chung EJ; Park SW; Lee WY
Mov Disord; 2006 Aug; 21(8):1261-4. PubMed ID: 16685692
[TBL] [Abstract][Full Text] [Related]
17. Valvular heart disease and fibrotic reactions may be related to ergot dopamine agonists, but non-ergot agonists may also not be spared.
Chaudhuri KR; Dhawan V; Basu S; Jackson G; Odin P
Mov Disord; 2004 Dec; 19(12):1522-3. PubMed ID: 15515009
[No Abstract] [Full Text] [Related]
18. Retroperitoneal fibrosis in a patient with Parkinson's disease treated with pergolide.
Jiménez-Jiménez FJ; López-Alvarez J; Sánchez-Chapado M; Montero E; Miquel J; Sierra A; Gutiérrez F
Clin Neuropharmacol; 1995 Jun; 18(3):277-9. PubMed ID: 8635187
[TBL] [Abstract][Full Text] [Related]
19. Dopamine agonists and valvular heart disease.
Kast RE; Altschuler EL
N Engl J Med; 2007 Apr; 356(16):1677; author reply 1678-80. PubMed ID: 17447278
[No Abstract] [Full Text] [Related]
20. [Cardiac valvulopathy and dopamine agonist].
Grandas F
Neurologia; 2007 Dec; 22(10):870-81. PubMed ID: 17671852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
